PR Newswire07.18.16
CEFALY Technology announced today that Cefaly, the first FDA-approved external trigeminal nerve stimulation device for the prevention of frequent episodic migraine attacks, has undergone a massive makeover. Cefaly I, which gained popularity for its headband-like shape, is now three-quarters its size, fits in the palm of your hand, is rechargeable, uses magnets to stay in place, and allows patients more control over the intensity of their daily session. The new Cefaly II is available exclusively in the United States; it will become available next in Europe in September.
"This compact device is so easy to tuck in a pocket or purse and I am hopeful it will further increase compliance and bring an even larger reduction in migraine attacks to patients," said Dr. Pierre Rigaux, the chief executive officer of CEFALY Technology, and a member of the team that invented the device. "Cefaly I has a tremendous success record. In clinical trials 81% of compliant patients showed a significant reduction in migraine attacks and up to a 75% reduction in consumption of migraine medications. Now that the device is so small, it's a big deal because patients can have their Cefaly II with them wherever they go, which means they'll be able to use it more readily, at their most convenient time."
Cefaly is an electronic, battery-powered, device that is placed on the forehead for 20-minutes once a day, using a self-adhesive electrode and a magnetic connection. The device sends tiny electrical impulses through the skin to desensitize the upper branches of the trigeminal nerve and reduce the frequency of migraine attacks. The new device allows patients to control their session by ramping up the intensity to their desired comfort level. Also, the introduction of a magnetic connection means the device will more quickly fall into place—and more securely maintain its connection—rather than be affixed to a fastener where a small movement could occasionally interrupt the session.
Also new is a built-in rechargeable Lithium-ion Polymer 3.7 V battery that replaces the two AAA batteries, which contributed to the device's shape and bulk. The new battery allows for the Cefaly II to be charged either by a USB cable on a home or work computer, or through a wall charger.
"This compact device is so easy to tuck in a pocket or purse and I am hopeful it will further increase compliance and bring an even larger reduction in migraine attacks to patients," said Dr. Pierre Rigaux, the chief executive officer of CEFALY Technology, and a member of the team that invented the device. "Cefaly I has a tremendous success record. In clinical trials 81% of compliant patients showed a significant reduction in migraine attacks and up to a 75% reduction in consumption of migraine medications. Now that the device is so small, it's a big deal because patients can have their Cefaly II with them wherever they go, which means they'll be able to use it more readily, at their most convenient time."
Cefaly is an electronic, battery-powered, device that is placed on the forehead for 20-minutes once a day, using a self-adhesive electrode and a magnetic connection. The device sends tiny electrical impulses through the skin to desensitize the upper branches of the trigeminal nerve and reduce the frequency of migraine attacks. The new device allows patients to control their session by ramping up the intensity to their desired comfort level. Also, the introduction of a magnetic connection means the device will more quickly fall into place—and more securely maintain its connection—rather than be affixed to a fastener where a small movement could occasionally interrupt the session.
Also new is a built-in rechargeable Lithium-ion Polymer 3.7 V battery that replaces the two AAA batteries, which contributed to the device's shape and bulk. The new battery allows for the Cefaly II to be charged either by a USB cable on a home or work computer, or through a wall charger.